AI assistant
Panacea Biotec Ltd. — Board/Management Information 2025
Apr 1, 2025
62573_rns_2025-04-01_34f822eb-a9e5-476e-b3da-7a28bd01bab7.pdf
Board/Management Information
Open in viewerOpens in your device viewer
==> picture [162 x 79] intentionally omitted <==
April 01, 2025
The Manager, Listing Department The National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 NSE Symbol: PANACEABIO
BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 BSE Scrip Code: 531349
Sub: Intimation of completion of tenure of Mr. Narotam Kumar Juneja, Director
Ref.: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Dear Sir / Madam,
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we would like to inform you that Mr. Narotam Kumar Juneja (DIN: 01204817), non-executive non-independent director of the Company was re-appointed as director liable to retire by rotation, in the Annual General Meeting (“AGM”) held on September 27, 2024, for a period upto March 31, 2025.
Accordingly, he has completed his tenure as non-executive non-independent director and consequently ceased to be the director of the Company on March 31, 2025. Accordingly, he has also ceased to be the Chairperson / member of the Committees of the Board of Directors of the Company.
Similarly, Mr. Narotam Kumar Juneja has also completed his tenure as Whole-time Director in the Company’s material subsidiary viz., Panacea Biotec Pharma Limited (“PBPL”) and consequently ceased to be the director of PBPL on March 31, 2025.
The Board of Directors and the Management of the Company express deep appreciation and gratitude to the aforesaid director for his contribution and guidance towards the business growth of the Company, during his association with the Company.
The details required to be disclosed under Regulation 30 of the SEBI LODR Regulations read along with SEBI circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are enclosed herewith as Annexure - A .
This is for your kind information and record please.
Thanking you, Sincerely yours, For Panacea Biotec Limited
Digitally signed by Vinod Goel Vinod Goel Date: 2025.04.01 08:42:33 +05'30'
Vinod Goel Group CFO and Head Legal & Company Secretary
Panacea Biotec Limited (CIN: L33117PB1984PLC022350) Regd. Office : Ambala Chandigarh Highway, Lalru – 140501, Punjab Correspondence/Corporate office : B-1 Extn../A-27 Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India Ph.: 91-11-4167 9000, 4167 8000, Email: [email protected]
==> picture [162 x 79] intentionally omitted <==
Annexure - A
| S. No. |
Particulars | Description | ||
|---|---|---|---|---|
| 1. | Reason for change viz.~~appointment,~~ ~~reappointment, resignation, removal,~~ ~~death~~or otherwise |
Mr. Narotam Kumar Juneja has ceased to be director upon completion of his tenure |
||
| 2. | Date of~~appointment / re-appointment /~~ cessation (as applicable)~~& term of~~ ~~appointment/re- appointment~~ |
March 31, 2025 | ||
| 3. | Brief profile, in case of appointment | Not Applicable | ||
| 4. | Disclosure of relationships between directors (in case of appointment of a director). |
Not Applicable |
Digitally signed by Vinod Goel Vinod Goel Date: 2025.04.01 08:42:57 +05'30'
Panacea Biotec Limited (CIN: L33117PB1984PLC022350) Regd. Office : Ambala Chandigarh Highway, Lalru – 140501, Punjab Correspondence/Corporate office : B-1 Extn../A-27 Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India Ph.: 91-11-4167 9000, 4167 8000, Email: [email protected]